|
1
|
Mechoulam R, Hanuš LO, Pertwee R and
Howlett AC: Early phytocannabinoid chemistry to endocannabinoids
and beyond. Nat Rev Neurosci. 15:757–764. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pacher P, Bátkai S and Kunos G: The
endocannabinoid system as an emerging target of pharmacotherapy.
Pharmacol Rev. 58:389–462. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Munson AE, Harris LS, Friedman MA, Dewey
WL and Carchman RA: Antineoplastic activity of cannabinoids. J Natl
Cancer Inst. 55:597–602. 1975. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Guzmán M: Cannabinoids: Potential
anticancer agents. Nat Rev Cancer. 3:745–755. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Fowler CJ: Delta(9)-tetrahydrocannabinol
and cannabidiol as potential curative agents for cancer: A critical
examination of the preclinical literature. Clin Pharmacol Ther.
97:587–596. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ladin DA, Soliman E, Griffin L and Van
Dross R: Preclinical and clinical assessment of cannabinoids as
anti-cancer agents. Front Pharmacol. 7:3612016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Torres S, Lorente M, Rodríguez-Fornés F,
Hernández-Tiedra S, Salazar M, García-Taboada E, Barcia J, Guzmán M
and Velasco G: A combined preclinical therapy of cannabinoids and
temozolomide against glioma. Mol Cancer Ther. 10:90–103. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Scott KA, Dalgleish AG and Liu WM: The
combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the
anticancer effects of radiation in an orthotopic murine glioma
model. Mol Cancer Ther. 13:2955–2967. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Basu S and Dittel BN: Unraveling the
complexities of canna-binoid receptor 2 (CB2) immune regulation in
health and disease. Immunol Res. 51:26–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Galve-Roperh I, Sánchez C, Cortés ML,
Gómez del Pulgar T, Izquierdo M and Guzmán M: Anti-tumoral action
of cannabinoids: Involvement of sustained ceramide accumulation and
extracellular signal-regulated kinase activation. Nat Med.
6:313–319. 2000. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Salazar M, Carracedo A, Salanueva IJ,
Hernández-Tiedra S, Lorente M, Egia A, Vázquez P, Blázquez C,
Torres S, García S, et al: Cannabinoid action induces
autophagy-mediated cell death through stimulation of ER stress in
human glioma cells. J Clin Invest. 119:1359–1372. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Velasco G, Sánchez C and Guzmán M:
Anticancer mechanisms of cannabinoids. Curr Oncol. 23:S23–S32.
2016.PubMed/NCBI
|
|
13
|
Powles T, te Poele R, Shamash J, Chaplin
T, Propper D, Joel S, Oliver T and Liu WM: Cannabis-induced
cytotoxicity in leukemic cell lines: The role of the cannabinoid
receptors and the MAPK pathway. Blood. 105:1214–1221. 2005.
View Article : Google Scholar
|
|
14
|
Scott KA, Shah S, Dalgleish AG and Liu WM:
Enhancing the activity of cannabidiol and other cannabinoids in
vitro through modifications to drug combinations and treatment
schedules. Anticancer Res. 33:4373–4380. 2013.PubMed/NCBI
|
|
15
|
Borrelli F, Pagano E, Romano B, Panzera S,
Maiello F, Coppola D, De Petrocellis L, Buono L, Orlando P and Izzo
AA: Colon carcinogenesis is inhibited by the TRPM8 antagonist
cannabigerol, a cannabis-derived non-psychotropic cannabinoid.
Carcinogenesis. 35:2787–2797. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fraguas-Sánchez AI, Fernández-Carballido A
and Torres-Suárez AI: Phyto-, endo- and synthetic cannabinoids:
Promising chemotherapeutic agents in the treatment of breast and
prostate carcinomas. Expert Opin Investig Drugs. 25:1311–1323.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Liu WM, Gravett AM and Dalgleish AG: The
antimalarial agent artesunate possesses anticancer properties that
can be enhanced by combination strategies. Int J Cancer.
128:1471–1480. 2011. View Article : Google Scholar
|
|
18
|
Liu WM, Scott KA, Shamash J, Joel S and
Powles TB: Enhancing the in vitro cytotoxic activity of
Delta9-tetrahydrocannabinol in leukemic cells through a
combinatorial approach. Leuk Lymphoma. 49:1800–1809. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chou TC: Drug combination studies and
their synergy quantification using the Chou-Talalay method. Cancer
Res. 70:440–446. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Van Dross R, Soliman E, Jha S, Johnson T
and Mukhopadhyay S: Receptor-dependent and receptor-independent
endocannabinoid signaling: A therapeutic target for regulation of
cancer growth. Life Sci. 92:463–466. 2013. View Article : Google Scholar
|
|
21
|
Rocha FC, Dos Santos Júnior JG, Stefano SC
and da Silveira DX: Systematic review of the literature on clinical
and experimental trials on the antitumor effects of cannabinoids in
gliomas. J Neurooncol. 116:11–24. 2014. View Article : Google Scholar
|
|
22
|
Jia W, Hegde VL, Singh NP, Sisco D, Grant
S, Nagarkatti M and Nagarkatti PS:
Delta9-tetrahydrocannabinol-induced apoptosis in Jurkat leukemia T
cells is regulated by translocation of Bad to mitochondria. Mol
Cancer Res. 4:549–562. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
McKallip RJ, Jia W, Schlomer J, Warren JW,
Nagarkatti PS and Nagarkatti M: Cannabidiol-induced apoptosis in
human leukemia cells: A novel role of cannabidiol in the regulation
of p22phox and Nox4 expression. Mol Pharmacol. 70:897–908. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu WM: Enhancing the cytotoxic activity
of novel targeted therapies - is there a role for a combinatorial
approach? Curr Clin Pharmacol. 3:108–117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
De Petrocellis L, Ligresti A, Schiano
Moriello A, Iappelli M, Verde R, Stott CG, Cristino L, Orlando P
and Di Marzo V: Non-THC cannabinoids inhibit prostate carcinoma
growth in vitro and in vivo: Pro-apoptotic effects and underlying
mechanisms. Br J Pharmacol. 168:79–102. 2013. View Article : Google Scholar :
|
|
26
|
Fisher T, Golan H, Schiby G, PriChen S,
Smoum R, Moshe I, Peshes-Yaloz N, Castiel A, Waldman D, Gallily R,
et al: In vitro and in vivo efficacy of non-psychoactive
cannabidiol in neuroblastoma. Curr Oncol. 23:S15–S22.
2016.PubMed/NCBI
|
|
27
|
Scott KA, Dennis JL, Dalgleish AG and Liu
WM: Inhibiting heat shock proteins can potentiate the cytotoxic
effect of cannabidiol in human glioma cells. Anticancer Res.
35:5827–5837. 2015.PubMed/NCBI
|
|
28
|
Tournigand C, André T, Achille E, Lledo G,
Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et
al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced
colorectal cancer: A randomized GERCOR study. J Clin Oncol.
22:229–237. 2004. View Article : Google Scholar
|
|
29
|
Dear RF, McGeechan K, Jenkins MC, Barratt
A, Tattersall MH and Wilcken N: Combination versus sequential
single agent chemotherapy for metastatic breast cancer. Cochrane
Database Syst Rev. 12:CD0087922013.
|
|
30
|
Bonner JA and Kozelsky TF: The
significance of the sequence of administration of topotecan and
etoposide. Cancer Chemother Pharmacol. 39:109–112. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Billard C: BH3 mimetics: Status of the
field and new developments. Mol Cancer Ther. 12:1691–1700. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shapiro GI and Harper JW: Anticancer drug
targets: Cell cycle and checkpoint control. J Clin Invest.
104:1645–1653. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shah MA and Schwartz GK: Cell
cycle-mediated drug resistance: An emerging concept in cancer
therapy. Clin Cancer Res. 7:2168–2181. 2001.PubMed/NCBI
|
|
34
|
Caffarel MM, Moreno-Bueno G, Cerutti C,
Palacios J, Guzman M, Mechta-Grigoriou F and Sanchez C: JunD is
involved in the antiproliferative effect of
Delta9-tetrahydrocannabinol on human breast cancer cells. Oncogene.
27:5033–5044. 2008. View Article : Google Scholar : PubMed/NCBI
|
